Detail

CHEPLAPHARM acquires product rights for ATACAND® and ATACAND® Plus from AstraZeneca in Europe

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose combination of Candesartan Cilexetil and Hydrochlorothiazide) in 28 European markets from AstraZeneca.

 

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose combination of Candesartan Cilexetil and Hydrochlorothiazide) in 28 European markets from AstraZeneca.

ATACAND® is a prescription medication for the treatment of heart failure and hypertension. The completion of the transaction is expected for the third quarter of 2018.

“This investment will already contribute significantly to our operating income in the fourth quarter of 2018”, said CHEPLAPHARM’s CEO Sebastian F. Braun. “Furthermore, this agreement matches perfectly with our internationally oriented business strategy and will strengthen our country portfolio and, consequently, realize and further develop our ambitious growth strategy in the respective territories.”

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com

Back